Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000004662
Ethics application status
Approved
Date submitted
12/07/2005
Date registered
12/07/2005
Date last updated
27/05/2013
Type of registration
Retrospectively registered
Titles & IDs
Public title
ASPIRE
Query!
Scientific title
A multi-centre, randomised, double-blind, placebo-controlled clinical trial examining the efficacy and safety of low-dose aspirin after initial anticoagulation to prevent recurrent venous thromboembolism
Query!
Secondary ID [1]
262166
0
CTRI/2007/091/000029
Query!
Secondary ID [2]
280367
0
ACTRN12611000684921 - INSPIRE is a prospective combined analysis of the ASPIRE and WARFASA studies
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ASPIRE
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Venous thromboembolism
66
0
Query!
Condition category
Condition code
Cardiovascular
78
78
0
0
Query!
Diseases of the vasculature and circulation including the lymphatic system
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
The ASPIRE study is an international multicentre, randomised, double-blind placebo controlled clinical trial designed to examine the efficacy and safety of low dose aspirin (100mg daily) to prevent recurrent deep venous thrombosis (DVT) or pulmonary embolism (PE) in patients with a first episide of unprovoked VTE who have completed initial treatment with heparin and warfarin.
Query!
Intervention code [1]
16
0
Prevention
Query!
Comparator / control treatment
Placebo
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
110
0
The primary outcome is the composite of objectively diagnosed symptomatic VTE or fatal PE
Query!
Assessment method [1]
110
0
Query!
Timepoint [1]
110
0
At the end of the study
Query!
Secondary outcome [1]
247
0
A) The composite of symptomatic VTE, myocardial infarction, stroke, or cardiovascular death (all serious thrombotic vascual events).
Query!
Assessment method [1]
247
0
Query!
Timepoint [1]
247
0
At the end of the study
Query!
Secondary outcome [2]
248
0
B) Symptomatic VTE , myocardial infarction, stroke, all cause mortality and major bleeding (a measure of net clinical benefit).
Query!
Assessment method [2]
248
0
Query!
Timepoint [2]
248
0
At the end of the study
Query!
Eligibility
Key inclusion criteria
First episode of unprovoked DVT or PE-completion of initial treatment with unfractionated heparin or low-molecular-weight heparin (or effective alternative) and warfarin (recommended treatment duration 6-24 months)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Allergy, intolerance or contraindication for aspirin-Clear indication for aspirin, clopidogrel or a conventional (COX 1/2) NSAID.-Indication for long-term anticoagulant therapy (eg prosthetic heart valve)-Life expectancy of less than 12 months-active bleeding or at high risk of bleeding-anticipated non-adherance to study medications-inability to attend follow-up because of geographical inaccessibility
Query!
Study design
Purpose of the study
Prevention
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation is via a secure web based allocation system
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Allocation concealment is maintained via a central web based allocation sytem using a computer programme. Randomisation is stratified by centre and duration of anticoagulant treatment (<26 weeks and > 26 weeks)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/05/2003
Query!
Actual
9/05/2003
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
11/08/2011
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
822
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,WA,VIC
Query!
Recruitment outside Australia
Country [1]
102
0
India
Query!
State/province [1]
102
0
Query!
Country [2]
103
0
New Zealand
Query!
State/province [2]
103
0
Query!
Country [3]
104
0
Singapore
Query!
State/province [3]
104
0
Query!
Country [4]
105
0
Argentina
Query!
State/province [4]
105
0
Query!
Funding & Sponsors
Funding source category [1]
108
0
Government body
Query!
Name [1]
108
0
National Health & Medical Research Council
Query!
Address [1]
108
0
Canberra
Query!
Country [1]
108
0
Australia
Query!
Funding source category [2]
109
0
Charities/Societies/Foundations
Query!
Name [2]
109
0
New Zealand Health Research Committee
Query!
Address [2]
109
0
110 Stanley Street, Auckland
Query!
Country [2]
109
0
New Zealand
Query!
Funding source category [3]
110
0
Government body
Query!
Name [3]
110
0
NSW Health
Query!
Address [3]
110
0
Melbourne, VIC
Query!
Country [3]
110
0
Australia
Query!
Funding source category [4]
111
0
Charities/Societies/Foundations
Query!
Name [4]
111
0
The Australasian Society of Thrombosis and Haemostasis
Query!
Address [4]
111
0
Pending
Query!
Country [4]
111
0
Australia
Query!
Funding source category [5]
112
0
Commercial sector/Industry
Query!
Name [5]
112
0
Bayer (study drug)
Query!
Address [5]
112
0
Leverkusen
Query!
Country [5]
112
0
Germany
Query!
Primary sponsor type
University
Query!
Name
NHMRC Clinical Trials Centre, University of Sydney
Query!
Address
Locked Bag 77. Camperdown. NSW 1450. Australia
Query!
Country
Australia
Query!
Secondary sponsor category [1]
83
0
None
Query!
Name [1]
83
0
None
Query!
Address [1]
83
0
Query!
Country [1]
83
0
Query!
Other collaborator category [1]
251990
0
University
Query!
Name [1]
251990
0
St John's Medical College
Query!
Address [1]
251990
0
Division of Clinical Trials
Institute of Population Health and Clinical Research
St. John?s National Academy of Health Sciences
Koramangala, Bangalore 560 034
India
Query!
Country [1]
251990
0
India
Query!
Other collaborator category [2]
251991
0
Commercial sector/Industry
Query!
Name [2]
251991
0
Estudios Cl?nicos Latinoam?rica
Query!
Address [2]
251991
0
Madres de Plaza 25 de Mayo 3020, piso 10
Torres Nordlink
2000 ? Rosario
Argentina
Query!
Country [2]
251991
0
Argentina
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
819
0
Box Hill Hospital
Query!
Ethics committee address [1]
819
0
Query!
Ethics committee country [1]
819
0
Australia
Query!
Date submitted for ethics approval [1]
819
0
Query!
Approval date [1]
819
0
Query!
Ethics approval number [1]
819
0
Query!
Ethics committee name [2]
820
0
Canberra Hospital
Query!
Ethics committee address [2]
820
0
Query!
Ethics committee country [2]
820
0
Australia
Query!
Date submitted for ethics approval [2]
820
0
Query!
Approval date [2]
820
0
Query!
Ethics approval number [2]
820
0
Query!
Ethics committee name [3]
821
0
Concord Hospital
Query!
Ethics committee address [3]
821
0
Query!
Ethics committee country [3]
821
0
Australia
Query!
Date submitted for ethics approval [3]
821
0
Query!
Approval date [3]
821
0
Query!
Ethics approval number [3]
821
0
Query!
Ethics committee name [4]
822
0
Flinders Medical Centre
Query!
Ethics committee address [4]
822
0
Query!
Ethics committee country [4]
822
0
Australia
Query!
Date submitted for ethics approval [4]
822
0
Query!
Approval date [4]
822
0
Query!
Ethics approval number [4]
822
0
Query!
Ethics committee name [5]
823
0
Geelong Hospital
Query!
Ethics committee address [5]
823
0
Query!
Ethics committee country [5]
823
0
Australia
Query!
Date submitted for ethics approval [5]
823
0
Query!
Approval date [5]
823
0
Query!
Ethics approval number [5]
823
0
Query!
Ethics committee name [6]
824
0
Gosford Hospital
Query!
Ethics committee address [6]
824
0
Query!
Ethics committee country [6]
824
0
Australia
Query!
Date submitted for ethics approval [6]
824
0
Query!
Approval date [6]
824
0
Query!
Ethics approval number [6]
824
0
Query!
Ethics committee name [7]
825
0
Mater Misercordiae Hospital
Query!
Ethics committee address [7]
825
0
Query!
Ethics committee country [7]
825
0
Australia
Query!
Date submitted for ethics approval [7]
825
0
Query!
Approval date [7]
825
0
Query!
Ethics approval number [7]
825
0
Query!
Ethics committee name [8]
826
0
Monash Medical Centre
Query!
Ethics committee address [8]
826
0
Query!
Ethics committee country [8]
826
0
Australia
Query!
Date submitted for ethics approval [8]
826
0
Query!
Approval date [8]
826
0
Query!
Ethics approval number [8]
826
0
Query!
Ethics committee name [9]
827
0
Prince of Wales Hospital
Query!
Ethics committee address [9]
827
0
Query!
Ethics committee country [9]
827
0
Australia
Query!
Date submitted for ethics approval [9]
827
0
Query!
Approval date [9]
827
0
Query!
Ethics approval number [9]
827
0
Query!
Ethics committee name [10]
828
0
Princess Alexandra Hoapital
Query!
Ethics committee address [10]
828
0
Query!
Ethics committee country [10]
828
0
Australia
Query!
Date submitted for ethics approval [10]
828
0
Query!
Approval date [10]
828
0
Query!
Ethics approval number [10]
828
0
Query!
Ethics committee name [11]
829
0
Queen Elizabeth Hospital
Query!
Ethics committee address [11]
829
0
Query!
Ethics committee country [11]
829
0
Australia
Query!
Date submitted for ethics approval [11]
829
0
Query!
Approval date [11]
829
0
Query!
Ethics approval number [11]
829
0
Query!
Ethics committee name [12]
830
0
Redcliffe Hospital
Query!
Ethics committee address [12]
830
0
Query!
Ethics committee country [12]
830
0
Australia
Query!
Date submitted for ethics approval [12]
830
0
Query!
Approval date [12]
830
0
Query!
Ethics approval number [12]
830
0
Query!
Ethics committee name [13]
831
0
Royal Brisbane & Women's Hospital
Query!
Ethics committee address [13]
831
0
Query!
Ethics committee country [13]
831
0
Australia
Query!
Date submitted for ethics approval [13]
831
0
Query!
Approval date [13]
831
0
Query!
Ethics approval number [13]
831
0
Query!
Ethics committee name [14]
832
0
Royal Hobart Hospital
Query!
Ethics committee address [14]
832
0
Query!
Ethics committee country [14]
832
0
Australia
Query!
Date submitted for ethics approval [14]
832
0
Query!
Approval date [14]
832
0
Query!
Ethics approval number [14]
832
0
Query!
Ethics committee name [15]
833
0
Royal North Shore Hospital
Query!
Ethics committee address [15]
833
0
Query!
Ethics committee country [15]
833
0
Australia
Query!
Date submitted for ethics approval [15]
833
0
Query!
Approval date [15]
833
0
Query!
Ethics approval number [15]
833
0
Query!
Ethics committee name [16]
834
0
Royal Perth Hospital
Query!
Ethics committee address [16]
834
0
Query!
Ethics committee country [16]
834
0
Australia
Query!
Date submitted for ethics approval [16]
834
0
Query!
Approval date [16]
834
0
Query!
Ethics approval number [16]
834
0
Query!
Ethics committee name [17]
835
0
St George Hospital
Query!
Ethics committee address [17]
835
0
Query!
Ethics committee country [17]
835
0
Australia
Query!
Date submitted for ethics approval [17]
835
0
Query!
Approval date [17]
835
0
Query!
Ethics approval number [17]
835
0
Query!
Ethics committee name [18]
836
0
St Vincent's Hospital Melbourne
Query!
Ethics committee address [18]
836
0
Query!
Ethics committee country [18]
836
0
Australia
Query!
Date submitted for ethics approval [18]
836
0
Query!
Approval date [18]
836
0
Query!
Ethics approval number [18]
836
0
Query!
Ethics committee name [19]
837
0
St Vincent's Hospital, Sydney
Query!
Ethics committee address [19]
837
0
Query!
Ethics committee country [19]
837
0
Australia
Query!
Date submitted for ethics approval [19]
837
0
Query!
Approval date [19]
837
0
Query!
Ethics approval number [19]
837
0
Query!
Ethics committee name [20]
838
0
The Alfred Hospital
Query!
Ethics committee address [20]
838
0
Query!
Ethics committee country [20]
838
0
Australia
Query!
Date submitted for ethics approval [20]
838
0
Query!
Approval date [20]
838
0
Query!
Ethics approval number [20]
838
0
Query!
Summary
Brief summary
The ASPIRE is looking at the effectiveness and safety of giving low-dose aspirin to prevent recurrent deep vein thrombosis (DVT) or pulmonary embolism (PE) in patients with a first episode of unprovoked venous thromboembolism (VTE) who have completed initial anticoagulant treatment with heparin and warfarin.
Recruitment has now closed, with 822 patients enrolled from centres in Australia, New Zealand, Singapore, India and Argentina.
The ASPIRE study addresses a question of major clinical and public health importance with several million patients at risk of recurrent VTE worldwide. If aspirin is found to be beneficial, this safe, inexpensive, and practicable intervention could be very widely applied and prevent thousands of patients from experiencing recurrent venous thromboembolism each year.
In Australia alone, a 30% reduction in risk of recurrent VTE could conservatively be expected to prevent 375 to 525 cases of venous thrombosis and save 56-80 lives in the first year.
Query!
Trial website
Query!
Trial related presentations / publications
Published in New England Journal of Medicine 2012. Also Late Breaking Clinical Trial at American Heart Association meeting in November 2012.
Reference: Brighton TA, Eikelboom JW, Mann K, Mister R, Gallus A, Ockelford P, Gibbs H, Hague W, Xavier D, Diaz R, Kirby A, Simes J; ASPIRE Investigators. Low-dose aspirin for preventing recurrent venous thromboembolism. New England Journal of Medicine 2012; 367(21): 1979–1987.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
35152
0
Dr Timothy Brighton
Query!
Address
35152
0
SEALS (Randwick)
Prince of Wales Hospital
Barker Street
Sydney, NSW, AUSTRALIA. 2031
Query!
Country
35152
0
Australia
Query!
Phone
35152
0
+61 2 9562 5342
Query!
Fax
35152
0
Query!
Email
35152
0
[email protected]
Query!
Contact person for public queries
Name
9205
0
Dr Dr Timothy Brighton
Query!
Address
9205
0
ASPIRE Study
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
Query!
Country
9205
0
Australia
Query!
Phone
9205
0
+61 2 95625342
Query!
Fax
9205
0
+61 2 95625094
Query!
Email
9205
0
[email protected]
Query!
Contact person for scientific queries
Name
133
0
Prof John Simes
Query!
Address
133
0
ASPIRE Study
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
Query!
Country
133
0
Australia
Query!
Phone
133
0
+61 2 95625342
Query!
Fax
133
0
+61 2 95625094
Query!
Email
133
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
Source
Title
Year of Publication
DOI
Embase
Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
2017
https://dx.doi.org/10.1002/14651858.CD011088.pub2
N.B. These documents automatically identified may not have been verified by the study sponsor.
Download to PDF